CO2017002292A2 - Compuestos y composiciones como inhibidores de quinasa raf - Google Patents
Compuestos y composiciones como inhibidores de quinasa rafInfo
- Publication number
- CO2017002292A2 CO2017002292A2 CONC2017/0002292A CO2017002292A CO2017002292A2 CO 2017002292 A2 CO2017002292 A2 CO 2017002292A2 CO 2017002292 A CO2017002292 A CO 2017002292A CO 2017002292 A2 CO2017002292 A2 CO 2017002292A2
- Authority
- CO
- Colombia
- Prior art keywords
- compounds
- compositions
- raf kinase
- kinase inhibitors
- salts
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
La presente invención proporciona un compuesto de Fórmula I: donde X, Y, Z, R1 y R2 son como se describen en el presente documento, y sales de los mismos y usos terapéuticos de estos compuestos para el tratamiento de trastornos asociados con la actividad de la quinasa RAF. La invención proporciona además composiciones farmacéuticas que comprenden estos compuestos, y composiciones que comprenden estos compuestos y un co-agente terapéutico
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462049469P | 2014-09-12 | 2014-09-12 | |
PCT/IB2015/056986 WO2016038581A1 (en) | 2014-09-12 | 2015-09-11 | Compounds and compositions as raf kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2017002292A2 true CO2017002292A2 (es) | 2017-06-20 |
Family
ID=54148595
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2017/0002292A CO2017002292A2 (es) | 2014-09-12 | 2017-03-08 | Compuestos y composiciones como inhibidores de quinasa raf |
Country Status (30)
Country | Link |
---|---|
US (2) | US9573969B2 (es) |
EP (1) | EP3191472B1 (es) |
JP (1) | JP6678655B2 (es) |
KR (1) | KR20170053686A (es) |
CN (1) | CN107108671B (es) |
AP (1) | AP2017009830A0 (es) |
AR (1) | AR101815A1 (es) |
AU (1) | AU2015313782B2 (es) |
BR (1) | BR112017004741A2 (es) |
CA (1) | CA2960971A1 (es) |
CL (1) | CL2017000541A1 (es) |
CO (1) | CO2017002292A2 (es) |
CR (1) | CR20170092A (es) |
CU (1) | CU20170026A7 (es) |
DO (1) | DOP2017000066A (es) |
EA (1) | EA031061B1 (es) |
EC (1) | ECSP17021897A (es) |
ES (1) | ES2729243T3 (es) |
IL (1) | IL250950A0 (es) |
MX (1) | MX2017003233A (es) |
NI (1) | NI201700029A (es) |
PE (1) | PE20171338A1 (es) |
PH (1) | PH12017500416A1 (es) |
SG (1) | SG11201701734QA (es) |
SV (1) | SV2017005405A (es) |
TN (1) | TN2017000075A1 (es) |
TW (1) | TWI603977B (es) |
UY (1) | UY36294A (es) |
WO (1) | WO2016038581A1 (es) |
ZA (1) | ZA201701633B (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
UY35391A (es) | 2013-03-14 | 2014-09-30 | Boehringer Ingelheim Int | Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-cianometil)-amidas sustituidas inhibidores de catepsina c |
KR20160122736A (ko) * | 2014-01-14 | 2016-10-24 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 헤테로아릴 및 이의 용도 |
UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
HUE047208T2 (hu) | 2014-09-12 | 2020-04-28 | Boehringer Ingelheim Int | A katepszin-C spirociklikus inhibitorai |
AU2017329090B9 (en) | 2016-09-19 | 2019-09-05 | Novartis Ag | Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor |
JP2020529411A (ja) * | 2017-08-03 | 2020-10-08 | ノバルティス アーゲー | 第三世代egfrチロシンキナーゼ阻害剤とraf阻害剤の治療用組合せ |
AU2020244761A1 (en) * | 2019-03-22 | 2021-11-11 | Kinnate Biopharma Inc. | Inhibitors of RAF kinases |
EP3962484A4 (en) | 2019-05-03 | 2023-01-18 | Kinnate Biopharma Inc. | RAF KINASE INHIBITORS |
MX2022004937A (es) * | 2019-10-24 | 2022-07-27 | Kinnate Biopharma Inc | Inhibidores de las cinasas raf. |
US11407737B2 (en) | 2020-09-18 | 2022-08-09 | Kinnate Biopharma Inc. | Inhibitors of RAF kinases |
WO2022066580A1 (en) * | 2020-09-23 | 2022-03-31 | Kinnate Biopharma Inc. | Raf degrading compounds |
WO2022081469A1 (en) | 2020-10-12 | 2022-04-21 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
IL307908A (en) | 2021-04-23 | 2023-12-01 | Kinnate Biopharma Inc | Cancer treatment with a RAF inhibitor |
JP2024517431A (ja) * | 2021-04-23 | 2024-04-22 | キネート バイオファーマ インク. | (s)-n-(3-(2-(((r)-1-ヒドロキシプロパン-2-イル)アミノ)-6-モルホリノピリジン-4-イル)-4-メチルフェニル)-3-(2,2,2-トリフルオロエチル)ピロリジン-1-カルボキサミドおよびその塩の固体状態での形態 |
WO2022238327A1 (en) * | 2021-05-12 | 2022-11-17 | Boehringer Ingelheim International Gmbh | Pyridine derivatives with n-linked cyclic substituents as cgas inhibitors |
Family Cites Families (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3707475A (en) | 1970-11-16 | 1972-12-26 | Pfizer | Antiinflammatory imidazoles |
DE3029376A1 (de) | 1980-07-31 | 1982-03-18 | Nepera Chemical Co. Inc., Harriman, N.Y. | Verfahren zur herstellung von 2,4,5-tris-pyridylimidazolen |
EP0149884B1 (en) | 1983-09-09 | 1992-12-16 | Takeda Chemical Industries, Ltd. | 5-pyridyl-1,3-thiazole derivatives, their production and use |
JP2722586B2 (ja) | 1989-01-13 | 1998-03-04 | 大正製薬株式会社 | インドリルイミダゾール誘導体 |
JP2808460B2 (ja) | 1989-11-16 | 1998-10-08 | 大正製薬株式会社 | イミダゾール誘導体 |
US6358932B1 (en) | 1994-05-31 | 2002-03-19 | Isis Pharmaceticals, Inc. | Antisense oligonucleotide inhibition of raf gene expression |
US5717100A (en) | 1995-10-06 | 1998-02-10 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
GB2306108A (en) | 1995-10-13 | 1997-04-30 | Merck & Co Inc | Treatment of Raf-mediated cancers with imidazole derivatives |
WO1998008845A1 (en) | 1996-08-27 | 1998-03-05 | Novartis Ag | Herbicidal s-substituted 1,2,4,6-thiatriazines |
WO1998038984A2 (en) | 1997-03-05 | 1998-09-11 | Sugen, Inc. | Formulations for hydrophobic pharmaceutical agents |
AR012634A1 (es) | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
GB9711650D0 (en) | 1997-06-05 | 1997-07-30 | Pfizer Ltd | Compounds useful in therapy |
GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
US6022884A (en) | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
US6211177B1 (en) | 1998-11-24 | 2001-04-03 | Cell Pathways, Inc. | Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives |
EP1140840B1 (en) | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US6548529B1 (en) | 1999-04-05 | 2003-04-15 | Bristol-Myers Squibb Company | Heterocyclic containing biphenyl aP2 inhibitors and method |
WO2000061576A1 (en) | 1999-04-09 | 2000-10-19 | Smithkline Beecham Corporation | Triarylimidazoles |
PL215901B1 (pl) | 1999-04-15 | 2014-02-28 | Bristol Myers Squibb Co | Cykliczny inhibitor bialkowych kinaz tyrozynowych, jego zastosowanie oraz kompozycja farmaceutyczna zawierajaca taki zwiazek |
JP2000302680A (ja) | 1999-04-23 | 2000-10-31 | Takeda Chem Ind Ltd | 脳保護剤 |
US6310574B1 (en) | 1999-08-05 | 2001-10-30 | Vega Grieshaber Kg | Level transmitter |
WO2001021598A1 (en) | 1999-09-23 | 2001-03-29 | Astrazeneca Ab | Therapeutic quinazoline compounds |
ATE382044T1 (de) | 1999-11-22 | 2008-01-15 | Smithkline Beecham Plc | Imidazol- derivate |
EP1251849A1 (en) | 2000-01-18 | 2002-10-30 | Vertex Pharmaceuticals Incorporated | Gyrase inhibitors and uses thereof |
SI1251848T1 (en) | 2000-01-18 | 2004-12-31 | Vertex Pharmaceuticals Incorporated | Gyrase inhibitors and uses thereof |
CO5271680A1 (es) | 2000-02-21 | 2003-04-30 | Smithkline Beecham Corp | Compuestos |
GB0005357D0 (en) | 2000-03-06 | 2000-04-26 | Smithkline Beecham Plc | Compounds |
JP2003525936A (ja) | 2000-03-06 | 2003-09-02 | スミスクライン ビーチャム パブリック リミテッド カンパニー | Rafキナーゼ阻害物質としてのイミダゾール誘導体 |
GB0007405D0 (en) | 2000-03-27 | 2000-05-17 | Smithkline Beecham Corp | Compounds |
WO2001074811A2 (en) | 2000-03-30 | 2001-10-11 | Takeda Chemical Industries, Ltd. | Substituted 1,3-thiazole compounds, their production and use |
US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
AU6272301A (en) | 2000-06-12 | 2001-12-24 | Eisai Co Ltd | 1,2-dihydropyridine compounds, process for preparation of the same and use thereof |
JP2004514669A (ja) | 2000-11-07 | 2004-05-20 | ブリストル−マイヤーズ スクイブ カンパニー | セリンプロテアーゼ阻害剤として有用な酸誘導体 |
JP4217480B2 (ja) | 2000-11-20 | 2009-02-04 | スミスクライン・ビーチャム・コーポレイション | 新規化合物 |
US7238813B2 (en) | 2000-11-29 | 2007-07-03 | Smithkline Beecham Corporation | Chemical compounds |
ATE341539T1 (de) | 2001-01-26 | 2006-10-15 | Chugai Pharmaceutical Co Ltd | Malonyl coa-decarboxylase inhibitoren als stoffwechselmodulatoren |
US7199124B2 (en) | 2001-02-02 | 2007-04-03 | Takeda Pharmaceutical Company Limited | JNK inhibitor |
US20030009034A1 (en) | 2001-03-22 | 2003-01-09 | Neil Wishart | Transition metal mediated process |
JP2002338537A (ja) | 2001-05-16 | 2002-11-27 | Mitsubishi Pharma Corp | アミド化合物およびその医薬用途 |
GB0112348D0 (en) | 2001-05-19 | 2001-07-11 | Smithkline Beecham Plc | Compounds |
GB0129260D0 (en) | 2001-12-06 | 2002-01-23 | Eisai London Res Lab Ltd | Pharmaceutical compositions and their uses |
US8299108B2 (en) | 2002-03-29 | 2012-10-30 | Novartis Ag | Substituted benzazoles and methods of their use as inhibitors of raf kinase |
CA2480638C (en) | 2002-03-29 | 2013-02-12 | Chiron Corporation | Substituted benzazoles and use thereof as raf kinase inhibitors |
AR039241A1 (es) | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
DE60327443D1 (de) | 2002-09-18 | 2009-06-10 | Pfizer Prod Inc | Neue oxazolverbindungen als inhibitoren des transforming growth factor (tgf) |
CN1681805A (zh) | 2002-09-18 | 2005-10-12 | 辉瑞产品公司 | 作为转化生长因子(tgf)抑制剂的新的咪唑类化合物 |
CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
US7531553B2 (en) | 2003-03-21 | 2009-05-12 | Amgen Inc. | Heterocyclic compounds and methods of use |
CN1863774B (zh) | 2003-10-08 | 2010-12-15 | Irm责任有限公司 | 用作蛋白激酶抑制剂的化合物和组合物 |
DE602004021838D1 (de) | 2003-10-16 | 2009-08-13 | Novartis Vaccines & Diagnostic | Substituierte benzazole und ihre verwendung als raf-kinase-hemmer |
JP5095216B2 (ja) | 2003-11-14 | 2012-12-12 | ローラス セラピューティクス インコーポレーテッド | アリールイミダゾールおよびその抗癌剤としての使用 |
CA2556944C (en) | 2004-03-05 | 2012-10-09 | Taisho Pharmaceutical Co., Ltd. | Thiazole derivative |
KR100749566B1 (ko) | 2004-04-21 | 2007-08-16 | 이화여자대학교 산학협력단 | Alk5 및/또는 alk4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체 |
US20060106020A1 (en) | 2004-04-28 | 2006-05-18 | Rodgers James D | Tetracyclic inhibitors of Janus kinases |
PE20060315A1 (es) | 2004-05-24 | 2006-05-15 | Irm Llc | Compuestos de tiazol como moduladores de ppar |
US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
GB0415367D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
GB0415364D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
GB0415365D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
JP2008511631A (ja) | 2004-08-31 | 2008-04-17 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | TGF−βインヒビターとしてのピリミジニルイミダゾール |
WO2006038734A1 (en) | 2004-10-08 | 2006-04-13 | Astellas Pharma Inc. | Pyridazinone derivatives cytokines inhibitors |
JP2008516962A (ja) | 2004-10-15 | 2008-05-22 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 血管傷害を治療する方法 |
JP2007246520A (ja) | 2006-02-15 | 2007-09-27 | Takeda Yuichiro | Rage阻害剤 |
WO2007118149A2 (en) | 2006-04-07 | 2007-10-18 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical Lollege | Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers |
WO2008071605A2 (en) | 2006-12-15 | 2008-06-19 | F. Hoffmann-La Roche Ag | Methods of treating inflammatory diseases |
KR101541203B1 (ko) | 2007-06-27 | 2015-07-31 | 아스트라제네카 아베 | 피라지논 유도체 및 폐 질환의 치료에서 그의 용도 |
JP2010532381A (ja) | 2007-06-29 | 2010-10-07 | サネシス ファーマシューティカルズ, インコーポレイテッド | Rafキナーゼ阻害剤として有用な複素環式化合物 |
AR067354A1 (es) | 2007-06-29 | 2009-10-07 | Sunesis Pharmaceuticals Inc | Compuestos utiles como inhibidores de la raf quinasa |
WO2009003998A2 (en) | 2007-07-02 | 2009-01-08 | Boehringer Ingelheim International Gmbh | Antiproliferative compounds based on 5-membered heterocycles |
WO2009007749A2 (en) | 2007-07-09 | 2009-01-15 | Astrazeneca Ab | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
AU2008276063B2 (en) | 2007-07-17 | 2013-11-28 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2009014637A2 (en) | 2007-07-19 | 2009-01-29 | Schering Corporation | Heterocyclic amide compounds as protein kinase inhibitors |
JP2010538003A (ja) | 2007-08-29 | 2010-12-09 | グラクソスミスクライン エルエルシー | チアゾールおよびオキサゾールキナーゼ阻害薬 |
TW200916458A (en) | 2007-09-05 | 2009-04-16 | Astrazeneca Ab | Heterocyclic compounds and methods of use thereof |
WO2009047163A1 (en) | 2007-10-10 | 2009-04-16 | F. Hoffmann-La Roche Ag | Methods of treating inflammatory diseases |
TW200940537A (en) | 2008-02-26 | 2009-10-01 | Astrazeneca Ab | Heterocyclic urea derivatives and methods of use thereof |
US8865732B2 (en) | 2008-03-21 | 2014-10-21 | Novartis Ag | Heterocyclic compounds and uses thereof |
EA201001456A1 (ru) | 2008-03-21 | 2011-06-30 | Новартис Аг | Новые гетероциклические соединения и их применение |
UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
JP2011524365A (ja) | 2008-06-11 | 2011-09-01 | アイアールエム・リミテッド・ライアビリティ・カンパニー | マラリアの処置に有用な化合物および組成物 |
EA019722B1 (ru) | 2008-07-24 | 2014-05-30 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | 3,4-диарилпиразолы в качестве ингибиторов протеинкиназ |
WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
JP5753093B2 (ja) | 2008-12-19 | 2015-07-22 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Atrキナーゼのインヒビターとして有用なピラジン誘導体 |
CN102361859A (zh) * | 2008-12-30 | 2012-02-22 | 米伦纽姆医药公司 | 用作Raf激酶抑制剂的杂芳基化合物 |
US8242260B2 (en) | 2009-08-28 | 2012-08-14 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
EP2470532A1 (en) * | 2009-08-28 | 2012-07-04 | Array Biopharma, Inc. | 1h-pyrazolo [ 3, 4-b]pyridine compounds for inhibiting raf kinase |
AU2010291206A1 (en) | 2009-09-04 | 2012-02-23 | Novartis Ag | Bipyridines useful for the treatment of proliferative diseases |
WO2011059610A1 (en) | 2009-11-10 | 2011-05-19 | Glaxosmithkline Llc | Benzene sulfonamide thiazole and oxazole compounds |
US9315491B2 (en) | 2009-12-28 | 2016-04-19 | Development Center For Biotechnology | Pyrimidine compounds as mTOR and PI3K inhibitors |
EA022458B1 (ru) | 2009-12-28 | 2016-01-29 | Дженерал Инкорпорейтед Ассошиэйшн Фарма Вэлли Проджект Саппортинг Организейшн | 1,3,4-оксадиазол-2-карбоксамидное соединение |
KR20110123657A (ko) | 2010-05-07 | 2011-11-15 | 에스케이케미칼주식회사 | 피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물 |
MX2012015100A (es) | 2010-06-25 | 2013-05-01 | Novartis Ag | Compuestos y composiciones de heteroarilo como inhibidores de cinasa de proteina. |
CN101993415B (zh) | 2010-09-15 | 2013-08-14 | 北京韩美药品有限公司 | 作为Hedgehog通路抑制剂的化合物以及包含该化合物的药物组合物及其应用 |
PE20141360A1 (es) | 2011-02-07 | 2014-10-13 | Plexxikon Inc | Compuestos y metodos para la modulacion de quinasas e indicaciones para los mismos. |
WO2013022766A1 (en) | 2011-08-05 | 2013-02-14 | Flynn Gary A | Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors |
PE20140909A1 (es) | 2011-09-01 | 2014-07-20 | Irm Llc | COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-KIT |
CN102993199A (zh) * | 2011-09-09 | 2013-03-27 | 山东轩竹医药科技有限公司 | 杂环取代的吡啶并吡咯激酶抑制剂 |
RU2616619C2 (ru) | 2011-09-21 | 2017-04-18 | Селлзоум Лимитед | Морфолино-замещенные производные мочевины или карбамата в качестве ингибиторов mtor |
WO2013164769A1 (en) | 2012-05-02 | 2013-11-07 | Lupin Limited | Substituted pyridine compounds as crac modulators |
KR20150020169A (ko) | 2012-05-15 | 2015-02-25 | 노파르티스 아게 | Abl1, abl2 및 bcr-abl1의 활성을 억제하기 위한 벤즈아미드 유도체 |
WO2014008214A1 (en) | 2012-07-02 | 2014-01-09 | Biogen Idec Ma Inc. | Biaryl-containing compounds as inverse agonists of ror-gamma receptors |
WO2014058691A1 (en) | 2012-10-08 | 2014-04-17 | Merck Sharp & Dohme Corp. | Inhibitors of irak4 activity |
US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
-
2015
- 2015-09-10 UY UY0001036294A patent/UY36294A/es not_active Application Discontinuation
- 2015-09-11 US US14/851,249 patent/US9573969B2/en active Active
- 2015-09-11 WO PCT/IB2015/056986 patent/WO2016038581A1/en active Application Filing
- 2015-09-11 SG SG11201701734QA patent/SG11201701734QA/en unknown
- 2015-09-11 EP EP15766660.3A patent/EP3191472B1/en active Active
- 2015-09-11 TN TN2017000075A patent/TN2017000075A1/en unknown
- 2015-09-11 PE PE2017000445A patent/PE20171338A1/es not_active Application Discontinuation
- 2015-09-11 AR ARP150102898A patent/AR101815A1/es unknown
- 2015-09-11 ES ES15766660T patent/ES2729243T3/es active Active
- 2015-09-11 TW TW104130161A patent/TWI603977B/zh not_active IP Right Cessation
- 2015-09-11 CU CUP2017000026A patent/CU20170026A7/es unknown
- 2015-09-11 CA CA2960971A patent/CA2960971A1/en not_active Abandoned
- 2015-09-11 JP JP2017513759A patent/JP6678655B2/ja active Active
- 2015-09-11 AP AP2017009830A patent/AP2017009830A0/en unknown
- 2015-09-11 BR BR112017004741A patent/BR112017004741A2/pt not_active IP Right Cessation
- 2015-09-11 KR KR1020177009468A patent/KR20170053686A/ko unknown
- 2015-09-11 CN CN201580061323.4A patent/CN107108671B/zh active Active
- 2015-09-11 AU AU2015313782A patent/AU2015313782B2/en not_active Ceased
- 2015-09-11 MX MX2017003233A patent/MX2017003233A/es unknown
- 2015-09-11 EA EA201790599A patent/EA031061B1/ru not_active IP Right Cessation
- 2015-09-11 CR CR20170092A patent/CR20170092A/es unknown
-
2017
- 2017-01-04 US US15/397,787 patent/US9809610B2/en active Active
- 2017-03-05 IL IL250950A patent/IL250950A0/en unknown
- 2017-03-06 PH PH12017500416A patent/PH12017500416A1/en unknown
- 2017-03-07 ZA ZA2017/01633A patent/ZA201701633B/en unknown
- 2017-03-07 CL CL2017000541A patent/CL2017000541A1/es unknown
- 2017-03-08 CO CONC2017/0002292A patent/CO2017002292A2/es unknown
- 2017-03-09 DO DO2017000066A patent/DOP2017000066A/es unknown
- 2017-03-10 SV SV2017005405A patent/SV2017005405A/es unknown
- 2017-03-10 NI NI201700029A patent/NI201700029A/es unknown
- 2017-04-07 EC ECIEPI201721897A patent/ECSP17021897A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NI201700029A (es) | Compuestos y composiciones como inhibidores de quinasa raf. | |
NI201500120A (es) | Compuestos de biaril - amida como inhibidores de cinasa | |
CO2018007528A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
DOP2016000085A (es) | Amino-heteroaril-benzamidas como inhibidores de cinasa | |
CO2017011851A2 (es) | Compuestos novedosos | |
CR20170384A (es) | Derivados de nucleosidos sustituidos utiles como agentes antineoplasicos | |
CR20180516A (es) | Compuestos de iprrolotriazina como inhibidores de tam | |
NI201600058A (es) | Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4 | |
CU20160188A7 (es) | Compuestos de indazole substituidos como inhibidores de irak4 | |
CR20150633A (es) | Derivados del bipirazol como inhibidores jak | |
UY35663A (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
UY35617A (es) | Inhibidores de la fosfatidilinositol 3-quinasa | |
UY35898A (es) | ?compuestos inhibidores de syk y composiciones que los comprenden?. | |
DOP2015000158A (es) | Inhibidores de prmt5 y sus usos | |
UY36875A (es) | Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades | |
CL2019000476A1 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2. | |
CL2017000827A1 (es) | Inhibidores de aldosterona sintasa | |
CL2017000040A1 (es) | Inhibidores de aldosterona sintasa. | |
DOP2020000100A (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3 | |
EA201891439A1 (ru) | Трициклические соединения и их композиции в качестве ингибиторов киназ | |
CR20160175A (es) | Amino-heteroaril-benzamidas como inhibidores de cinasa | |
UY35672A (es) | Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos |